Production (Stage)
Protara Therapeutics, Inc.
TARA
$3.12
-$0.10-3.11%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.98M | 4.81M | 4.26M | 4.27M | 4.10M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.12M | 14.31M | 12.33M | 10.66M | 11.85M |
| Operating Income | -14.12M | -14.31M | -12.33M | -10.66M | -11.85M |
| Income Before Tax | -11.91M | -12.77M | -11.22M | -9.51M | -11.10M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -11.91M | -12.77M | -11.22M | -9.51M | -11.10M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -11.91M | -12.77M | -11.22M | -9.51M | -11.10M |
| EBIT | -14.12M | -14.31M | -12.33M | -10.66M | -11.85M |
| EBITDA | -14.04M | -14.23M | -12.25M | -10.58M | -11.77M |
| EPS Basic | -0.29 | -0.48 | -0.50 | -0.45 | -0.97 |
| Normalized Basic EPS | -0.18 | -0.30 | -0.31 | -0.28 | -0.61 |
| EPS Diluted | -0.29 | -0.48 | -0.50 | -0.45 | -0.97 |
| Normalized Diluted EPS | -0.18 | -0.30 | -0.31 | -0.28 | -0.61 |
| Average Basic Shares Outstanding | 40.71M | 26.43M | 22.33M | 21.23M | 11.42M |
| Average Diluted Shares Outstanding | 40.71M | 26.43M | 22.33M | 21.23M | 11.42M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |